124 related articles for article (PubMed ID: 26552957)
21. First-generation genomic tests for breast cancer treatment.
Andre F; Delaloge S
Lancet Oncol; 2010 Jan; 11(1):6-7. PubMed ID: 20005177
[No Abstract] [Full Text] [Related]
22. Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?
Lamond NW; Skedgel C; Younis T
Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):243-50. PubMed ID: 23570435
[TBL] [Abstract][Full Text] [Related]
23. 21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.
Lynch JA; Berse B; Coomer N; Kautter J
Genet Med; 2017 Oct; 19(10):1134-1143. PubMed ID: 28333918
[TBL] [Abstract][Full Text] [Related]
24. When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.
Brewer NT; Edwards AS; O'Neill SC; Tzeng JP; Carey LA; Rimer BK
Breast Cancer Res Treat; 2009 Sep; 117(1):25-9. PubMed ID: 18785002
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further Evolution.
Kim JY; Kim SI; Paik S
JAMA Oncol; 2016 Feb; 2(2):180-2. PubMed ID: 26633601
[No Abstract] [Full Text] [Related]
26. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
27. What is the value of the 21 gene recurrence score in HER2-negative patients?
Rosman M; Mylander WC; Tafra L
J Clin Oncol; 2010 Nov; 28(31):e647; author reply e648. PubMed ID: 20876423
[No Abstract] [Full Text] [Related]
28. What can breast cancer molecular sub-classification add to conventional diagnostic tools?
André F; Domont J; Delaloge S
Ann Oncol; 2007 Jul; 18 Suppl 9():ix33-6. PubMed ID: 17631593
[No Abstract] [Full Text] [Related]
29. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
[TBL] [Abstract][Full Text] [Related]
30. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
El Hage Chehade H; Wazir U; Mokbel K; Kasem A; Mokbel K
Am J Surg; 2018 Jan; 215(1):171-178. PubMed ID: 28622841
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic factors of early breast cancer].
Almagro E; González CS; Espinosa E
Med Clin (Barc); 2016 Feb; 146(4):167-71. PubMed ID: 25726309
[TBL] [Abstract][Full Text] [Related]
32. Clinical Application of Detecting 21-Gene Recurrence Score in Predicating Prognosis and Therapy Response of Patients with Breast Cancer from Two Medical Centers.
Xiao G; Meng J; Zhang J; Li G; Du N; Qin S; Wang J; Xu C; Ren H; Tang SC; Sun X
Cancer Invest; 2017 Nov; 35(10):639-646. PubMed ID: 29243989
[TBL] [Abstract][Full Text] [Related]
33. Genomic profile of breast cancer.
Plun-Favreau J; Svedman C; Valentine W; Rouzier R
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):393-4. PubMed ID: 25797274
[No Abstract] [Full Text] [Related]
34. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
35. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
36. Another ingredient added to HER2 mix.
Titus K
CAP Today; 1999 Nov; 13(11):1, 20-4, 26 passim. PubMed ID: 10724678
[No Abstract] [Full Text] [Related]
37. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Yardley DA; Peacock NW; Shastry M; Burris HA; Bechhold RG; Hendricks CB; Yoshizawa CN; Sing AP; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(2):299-308. PubMed ID: 26507191
[TBL] [Abstract][Full Text] [Related]
38. [Modern pharmacological therapy of breast cancer].
Láng I; Kahán Z; Hitre E; Dank M; Rubovszky G; Horváth Z; Kásler M
Orv Hetil; 2012 Jan; 153(2):56-65. PubMed ID: 22217685
[TBL] [Abstract][Full Text] [Related]
39. Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.
Ribnikar D; Bedard PL
Future Oncol; 2017 Dec; 13(30):2733-2736. PubMed ID: 29168649
[No Abstract] [Full Text] [Related]
40. Usefulness of Multigene Testing: Catching the Train That's Left the Station.
Swisher EM
JAMA Oncol; 2015 Oct; 1(7):951-2. PubMed ID: 26270409
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
